Predicting improvement in functional outcomes with aripiprazole

Open label naturalistic six month study of aripiprazole in schizophrenia measuring functional outcomes and positive, negative and cognitive symptoms

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000486628

Acronym

Double A Study

Enrollment

Registered

2005-09-23

Start date

2004-07-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Open label naturalistic flexible dosing study with aripiprazole for six months.

Study design

Allocation

Non-randomised trial

Intervention model

Single group

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

DSM-IV diagnosis of schizophrenia or related disorder.

Exclusion criteria

IQ<70; inability to communicate in English language; head injury or neurological disorder; acute drug intoxication.

Outcome results